[Current and future therapeutic options for COVID-19]. 2022

Marloes Dankers, and H Marjorie J M G Nelissen-Vrancken, and Marjolein Y Berger, and Marc J M Bonten, and Joop M A van Gerven, and Peter W A Kunst, and Majon Muller, and Marcel G M Olde Rikkert, and Frits R Rosendaal
Instituut Verantwoord Medicijngebruik, Utrecht.

The anti-inflammatory agents dexamethasone (corticosteroid), and tocilizumab and sarilumab (IL6-inhibitors) are effective in the treatment of late COVID-19. Other anti-inflammatory agents, like anakinra (IL1-inhibitor), baricitinib and tofacitinib (JAK-inhibitors) and lenzilumab (GM-CSF-inhibitor) have also shown positive results in late COVID-19. For the treatment of early COVID-19, the inhalation corticosteroid budesonide is regarded as an off-label treatment option. Virus-inhibitors, like remdesivir, molnupiravir and nirmatrelvir/ritonavir decrease the risk of hospitalization and the development of severe COVID-19 by patients with early symptoms. Monoclonal antibodies have shown limited or no efficacy against the omicron-variant of SARS-CoV-2. Fluvoxamine, l-arginine, AT-527 and ensovibep are considered as potential promising new therapies for the treatment of early COVID-19.

UI MeSH Term Description Entries
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D006157 Guanosine Monophosphate A guanine nucleotide containing one phosphate group esterified to the sugar moiety and found widely in nature. 5'-Guanylic Acid,Guanosine 5'-Monophosphate,5'-GMP,Guanylic Acid,5' Guanylic Acid,5'-Monophosphate, Guanosine,Acid, 5'-Guanylic,Acid, Guanylic,Guanosine 5' Monophosphate,Monophosphate, Guanosine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000093485 COVID-19 Drug Treatment The use of DRUGS to treat COVID19 or its symptoms. COVID-19 Drug Therapy,COVID19 Drug Therapy,COVID19 Drug Treatment,Coronavirus Disease 2019 Drug Treatment,Coronavirus Disease-19 Drug Treatment,COVID 19 Drug Therapy,COVID 19 Drug Treatment,COVID-19 Drug Therapies,COVID19 Drug Therapies,COVID19 Drug Treatments,Coronavirus Disease 19 Drug Treatment,Drug Therapy, COVID-19,Drug Therapy, COVID19,Therapy, COVID-19 Drug,Therapy, COVID19 Drug,Treatment, COVID-19 Drug
D000305 Adrenal Cortex Hormones HORMONES produced by the ADRENAL CORTEX, including both steroid and peptide hormones. The major hormones produced are HYDROCORTISONE and ALDOSTERONE. Adrenal Cortex Hormone,Corticoid,Corticoids,Corticosteroid,Corticosteroids,Cortex Hormone, Adrenal,Hormone, Adrenal Cortex,Hormones, Adrenal Cortex
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D063088 Phosphoramides Amide derivatives of phosphoric acid such as compounds that include the phosphoric triamide (P(

Related Publications

Marloes Dankers, and H Marjorie J M G Nelissen-Vrancken, and Marjolein Y Berger, and Marc J M Bonten, and Joop M A van Gerven, and Peter W A Kunst, and Majon Muller, and Marcel G M Olde Rikkert, and Frits R Rosendaal
January 2020, Frontiers in pharmacology,
Marloes Dankers, and H Marjorie J M G Nelissen-Vrancken, and Marjolein Y Berger, and Marc J M Bonten, and Joop M A van Gerven, and Peter W A Kunst, and Majon Muller, and Marcel G M Olde Rikkert, and Frits R Rosendaal
January 2022, European journal of medical research,
Marloes Dankers, and H Marjorie J M G Nelissen-Vrancken, and Marjolein Y Berger, and Marc J M Bonten, and Joop M A van Gerven, and Peter W A Kunst, and Majon Muller, and Marcel G M Olde Rikkert, and Frits R Rosendaal
January 2022, Infectious disorders drug targets,
Marloes Dankers, and H Marjorie J M G Nelissen-Vrancken, and Marjolein Y Berger, and Marc J M Bonten, and Joop M A van Gerven, and Peter W A Kunst, and Majon Muller, and Marcel G M Olde Rikkert, and Frits R Rosendaal
October 2022, Expert opinion on pharmacotherapy,
Marloes Dankers, and H Marjorie J M G Nelissen-Vrancken, and Marjolein Y Berger, and Marc J M Bonten, and Joop M A van Gerven, and Peter W A Kunst, and Majon Muller, and Marcel G M Olde Rikkert, and Frits R Rosendaal
September 2020, Infectious microbes & diseases,
Marloes Dankers, and H Marjorie J M G Nelissen-Vrancken, and Marjolein Y Berger, and Marc J M Bonten, and Joop M A van Gerven, and Peter W A Kunst, and Majon Muller, and Marcel G M Olde Rikkert, and Frits R Rosendaal
June 2022, Journal of clinical medicine,
Marloes Dankers, and H Marjorie J M G Nelissen-Vrancken, and Marjolein Y Berger, and Marc J M Bonten, and Joop M A van Gerven, and Peter W A Kunst, and Majon Muller, and Marcel G M Olde Rikkert, and Frits R Rosendaal
March 2021, Molecular pharmaceutics,
Marloes Dankers, and H Marjorie J M G Nelissen-Vrancken, and Marjolein Y Berger, and Marc J M Bonten, and Joop M A van Gerven, and Peter W A Kunst, and Majon Muller, and Marcel G M Olde Rikkert, and Frits R Rosendaal
August 2020, Life sciences,
Marloes Dankers, and H Marjorie J M G Nelissen-Vrancken, and Marjolein Y Berger, and Marc J M Bonten, and Joop M A van Gerven, and Peter W A Kunst, and Majon Muller, and Marcel G M Olde Rikkert, and Frits R Rosendaal
January 2022, Journal of central nervous system disease,
Marloes Dankers, and H Marjorie J M G Nelissen-Vrancken, and Marjolein Y Berger, and Marc J M Bonten, and Joop M A van Gerven, and Peter W A Kunst, and Majon Muller, and Marcel G M Olde Rikkert, and Frits R Rosendaal
June 2019, Liver international : official journal of the International Association for the Study of the Liver,
Copied contents to your clipboard!